Use of intravesical capsaicin for urge urinary incontinence and irritative voiding syndromes

Current Opinion in Urology

Volumn 8, Issue 4, 1998, Pages 293-296

  Hussain, Iqbal F ^a   Fowler, Clare J ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CAPSAICIN; LIDOCAINE; RESINIFERATOXIN; VANILLOID RECEPTOR;

BINDING SITE; BLADDER BIOPSY; BLADDER CAPACITY; BLADDER PRESSURE; DESENSITIZATION; DETRUSOR DYSSYNERGIA; EXCITATION; HUMAN; MICTURITION; MULTIPLE SCLEROSIS; MUSCLE SPINDLE AFFERENT NERVE; NEUROGENIC BLADDER; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SPINAL CORD INJURY; URGE INCONTINENCE; URODYNAMICS;

EID: 0031848914     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199807000-00006     Document Type: Short Survey

References (23)

1. Dasgupta P, Fowler CJ. Chillies: from antiquity to urology. Br J Urol 1997; 80:845-852. This is an excellent review of the origin, chemistry, physiology and eventual introduction cf capsaicin in modern uroneurology. The emphasis is on the historical, but the article also traces the concepts behind the application of intravesical capsaicin for the treatment of detrusor hyperreflexia.
2. Nelson EK, Dowson LE. The constitution of capsaicin the pungent princile of capsicum. J Am Chem Soc 1923; 45:2179.
3. Jancso N, Jancso Gabor A. Desensitisation of sensory nerve endings [in Hungarian]. Kiserl Orvostud 1949; 2:15.
4. Maggi CA Capsaicin and primary afferent neurons: from basic science to human therapy? J Auton Nerv Syst 1991; 33:1-14.
5. Jancso N, Lin K, Armstrong D, Pardo EG (editors). Desensitization with capsaicin and related acylamides as a tool for studying the function of pain receptors. In: Pharmacology of pain. Oxford: Pergamon Press; 1968. pp. 33-55.
6. Bevan S, James IF, Rang HP, et al. The mechanism of action of capsaicin: a sensory neurotoxin. In: Jenner P (editor). Neurotoxins and their pharmacological applications. New York: Raven Press; 1987. pp. 261-277.
7. Szallasi A. The vanilloid (capsaicin) receptor: receptor types and species differences. Gen Pharmacol 1994; 25:223-243.
8. Szallasi A. Autoradiographic visualisation and pharmacological characteristics of vanilloid (capsaicin) receptors in several species, including man. Acta Physiol Scand 1995; 155:629.
9. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389:816-824. This is a report of the isolation of a functional complementary DNA encoding a capsaicin receptor from sensory neurons, named the vanilloid receptor subtype 1.
10. de Groat WC, Kawatani M, Hisamitsu T, Cheng CL, Ma CP, Thor K, Steers W, Ropollo JR. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990; 30:S71-S78.
11. Cheng CL, de Groat WC. Changes in the afferent pathway for the micturition reflex after spinal cord injury in the cat. J Urol 1997; 157:80.
12. Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC. Intravesical capsaicin for neurogenic bladder dysfunction [letter]. Lancet 1992; 339:1239.
13. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57:169-173.
14. Chandiramani VA, Peterson T, Duthie GS, Fowler CJ. Urodynamic changes during therapeutic intravesical instillations of capsaicin. Br J Urol 1996; 77:792-797.
15. Fontanella UA, Rossi CA, Stephen RL. Bladder and urethral anaesthesia with electromotive drug administration (EMDA): a technique for invasive endoscopic procedures. Br J Urol 1997; 79:414-420.
16. Das A, Shupp-Byrne D, Rivas DA, Sedor J, Crewalk JA, Flood H, et al. Intravesical capsaicin for neurogenic bladder dysfunction. J Urol 1997; 157:352.
17. De-Ridder D, Chandiramani VA, Dasgupta P, Van Poppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperretlexia: a dual centre study with long term follow up. J Urol 1997; 158:2087-2092. This is a report of a large, dual centre European study on the use of intravesical capsaicin for the treatment of detrusor hyperreflexia. A total of 79 patients, who were unresponsive to oral anticholinergic therapy, were treated. Overall, 80% of patients derived some clinical benefit, although only 44% were able to achieve complete continence. A number of patients in this study have been followed up for 5 years and received multiple instillations of intravesical capsaicin with good clinical effect.
18. Dasgupta P, Chandiramani VA, Parkinson MC, Beckett A, Fowler CJ. Treating the human bladder with capsaicin: is it safe? Eur Urol 1998; 33:28-31. This paper suggests that patients receiving intravesical capsaicin instillations should have annual flexible cystoscopic bladder biopsies to look for premalignant or malignant change.
19. Cruz F, Avelino A, Coimbra A. Intravesical resiniferatoxin desensitizes bladder sensory fibres in a dose-dependent manner. J Urol 1997; 157:79
20. Cruz F, Guimaraes M, Silva C, Reis M. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1997; 350.
21. Appendino G, Szallasi A. Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci 1997; 60:681-696.
22. Bögi K, Lorenzo PS, Szállási Z, Acs P, Wagner GS, Blumberg PM. Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cδ: possible correlation with tumor-promoting activity. Cancer Res 1998; 58:1423-1428.
23. Lazzeri M, Beneforti P, Turini D. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 1997; 158:2093-2096. Fifteen patients were treated with intravesical resiniferatoxin. The authors found substantial differences in urodynamic effect between resiniferatoxin and capsaicin and suggest that further studies are required.